---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-276062"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:12:11.065347+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corbus Q3 net loss $23.3M ($1.90/sh); cash $104M; CRB-701 ORR 47.6% in HNSCC

## Summary
- Net loss of $23.3M ($1.90 diluted EPS) vs $13.8M ($1.15) in Q3 2024; operating expenses up $8.9M.
- Cash, equivalents $104M at Sep 30; raised $73.8M net in Oct-Nov offering extending runway into 2028.
- CRB-701 ESMO data: ORR 47.6% (HNSCC), 37.5% (cervical), 55.6% (mUC) at 3.6 mg/kg; registrational study planned mid-2026.
- CRB-913 SAD/MAD study on track; Ph1b in obese patients to start Q4 2025.
- CRB-601 Phase 1 dose escalation ongoing; first participant dosed Dec 2024.

## SEC filing metadata
- accession: 0001193125-25-276062
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312525276062/0001193125-25-276062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312525276062/crbp-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-276062
- JSON: https://secwatch.observer/filing/0001193125-25-276062.json
- Plain text: https://secwatch.observer/filing/0001193125-25-276062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.